First Quarterly Report 2026 of Huadong Medicine Co., Ltd.
Stock code: 000963
Stock abbreviation: Huadong Medicine
Announcement No.: 2026-030
Huadong Medicine Co., Ltd.
First Quarterly Report 2026
The Company and all members of the Board of Directors hereby guarantee that the information presented in this report is
authentic, accurate and complete and free of any false records, misleading statements or material omissions.
Important Declaration:
1. The Board of Directors, directors and senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as the
"Company") hereby guarantee that the information presented in the Report is authentic, accurate and complete and free of false
records, misleading statements or material omissions, and shall undertake individual and joint legal liabilities.
2. The Company's legal representative, the officer in charge of accounting, and the head of Accounting Department (accounting
manager) hereby declare that the financial information in this quarterly report is authentic, accurate and complete.
3. Has the First Quarterly Report been audited?
□Yes No
According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if listed companies have both Chinese and other language
version of public notice, they should ensure the content of both versions are the same. In the case of discrepancy, the original
version in Chinese shall prevail.
1
First Quarterly Report 2026 of Huadong Medicine Co., Ltd.
I. Key Financial Data
(I) Key accounting data and financial indicators
Whether the Company needs to perform a retroactive adjustment or restatement of previous accounting data
□Yes No
11,183,450,824.27
10,735,787,899.82
Year-on-year change for the
reporting period (%)
4.17%
1,002,189,357.16
914,708,484.70
9.56%
989,719,668.99
897,337,982.42
10.30%
-852,335,762.63
-832,728,693.88
-2.35%
0.5715
0.5224
9.40%
0.5715
0.5213
9.63%
3.97%
3.88%
0.09%
Current reporting period
Operating revenue (RMB)
Net profits attributable to
shareholders of the listed
company (RMB)
Net profits attributable to
shareholders of the listed
company after deduction of
non-recurring profit and loss
(RMB)
Net cash flow from operating
activities (RMB)
Basic earnings per share
(RMB/share)
Diluted earnings per share
(RMB/share)
Weighted average return on
equity
Total assets (RMB)
Owners' equity attributable to
shareholders of listed
companies (RMB)
End of the current reporting
period
39,908,042,564.94
Same period last year
39,038,036,320.92
Change from prior year-end
(%)
2.23%
24,811,339,992.99
3.71%
End of the last year
25,733,074,032.10
The Company's total share capital as of the trading day prior to disclosure:
The Company’s total share capital as of the trading day prior to
disclosure (shares)
Fully diluted earnings per share based on the latest share capital:
1,753,736,848.00
Preferred dividends paid (RMB)
Paid perpetual bond interest (RMB)
Fully diluted earnings per share based on the latest share capital
(RMB/share)
0.00
0.00
0.5715
(II) Non-recurring profit and loss items and amounts
Applicable □Not applicable
Unit: RMB
Item
Profits/losses on disposal of non-current
assets (including the written-off part of
the accrued impairment provision of
assets)
Government grants included in the
Amount during the current reporting
period
Description
534,949.84
22,334,120.97
2
First Quarterly Report 2026 of Huadong Medicine Co., Ltd.
current profits and losses (except those
that are closely related to the normal
business operation of the Company,
comply with national policies and
regulations, are enjoyed in accordance
with the defined criteria, and have a
lasting impact on the Company's profits
and losses)
Other non-operating revenue and
expenses other than those mentioned
above
-7,779,473.38
Less: Amount affected by income tax
1,182,827.86
Amount affected by minority
interests (after tax)
1,437,081.40
Total
12,469,688.17
--
Details of other profit and loss items conforming to th